Sucrobind Tablet contains the active component sucroferric oxyhydroxide. It is classified as a phosphate binder. This medication treats hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis. Hyperphosphatemia is characterized by abnormally high levels of phosphate in the blood, a common complication of CKD. This medicine contains iron, which can benefit individuals with CKD who often experience iron deficiency anemia. Providing iron and phosphate binding helps address iron deficiency and support red blood cell production.

You should not take Sucrobind Tablet if you are allergic to it or its components. Allergic reactions can range from mild to severe and may include symptoms such as rash, itching, swelling, dizziness, or difficulty breathing. Patients with iron overload disorders, such as hemochromatosis (iron overload disorder), or those receiving high-dose intravenous iron therapy should use Sucrobind Tablet cautiously. The use of this medicine in pediatric patients has not been extensively studied, and its safety and effectiveness in this population have yet to be established.

• Treatment of high phosphate levels in the blood

Sucrobind Tablet is a medication that effectively lowers elevated phosphate levels in the blood, primarily in patients with chronic kidney disease (CKD) who are on dialysis. By binding to dietary phosphate in the gastrointestinal tract, this medication prevents its absorption into the bloodstream, thereby reducing the overall phosphate burden. This helps to manage hyperphosphatemia, a common complication of CKD, and minimize associated risks such as bone disease and cardiovascular complications.

Inform the doctor about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Sucrobind Tablet, reducing effectiveness by causing undesirable side effects.

• Stored at controlled room temperature, between 20°C to 25°C (68°F to 77°F).
• Keep away from moisture, heat, and light.
• It should not be frozen.
• Keep away from children and pets.

To use Sucrobind Tablet, follow the instructions provided by your healthcare professional or the guidelines on the medication packaging. Typically, this medication is taken orally as chewable tablets with meals or shortly after eating. The dosage and frequency of administration will depend on your specific medical condition and individual needs. It is important to chew the tablets thoroughly before swallowing. You may consult your healthcare provider for alternative administration options if you have difficulty chewing.

Sucrobind tablets cause some side effects like all medications, although not everyone will experience them. 

Serious:

• Allergic reaction
• Breathlessness
• Black stools

Common:

• Diarrhea
• Discolored feces (usually dark or black)
• Constipation
• Nausea
• Vomiting
• Stomach pain or discomfort
• Indigestion or heartburn

When taking Sucrobind Tablet, it is important to note that allergic reactions are rare, but when to occur it requires immediate medical attention for symptoms like rash, itching, swelling, difficulty breathing, or dizziness develop. This medication contains iron and may contribute to iron overload, particularly in at-risk individuals, necessitating regular monitoring of iron levels. Caution should be exercised in individuals with gastrointestinal disorders. The safety during pregnancy, breastfeeding, and in pediatric patients has not been well established. Precautions should be taken to minimize the risk of tooth discoloration by performing good oral hygiene practices. Regular communication with healthcare providers is essential to address concerns and promptly report any concerning symptoms or side effects.

1. Vifor Fresenius Medical Care Renal Pharma France, Electronic medicines compendium (EMC), [Revised on Nov 2020] [ Accessed on 22nd June 2023], https://www.medicines.org.uk/emc/files/pil.3532.pdf
2. Fresenius Medical Care North America, US Food and Drug Administration, [Revised on Sept 2014] [ Accessed on 22nd June 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205109s001lbl.pdf